Hyperammonemia-induced toxicity for the developing central nervous system

Brain Research Reviews

Volumn 56, Issue 1, 2007, Pages 183-197

  Cagnon, Laurène ^a   Braissant, Olivier ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Ammonium; Brain; Development; Hyperammonemia; Neuroprotection; Neurotoxicity

Indexed keywords

ARGININE; ARYLBUTYRIC ACID DERIVATIVE; CARBAMOYL PHOSPHATE SYNTHASE; CARNITINE; CITRULLINE; CREATINE; GLUTAMIC ACID; GLUTAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; ORNITHINE; ORNITHINE CARBAMOYLTRANSFERASE; SODIUM CHLORIDE;

ACIDURIA; BRAIN CELL; BRAIN CORTEX ATROPHY; BRAIN DAMAGE; BRAIN METABOLISM; BRAIN VENTRICLE DILATATION; CARBAMOYLPHOSPHATE SYNTHETASE 1 DEFICIENCY; CELL GROWTH; CEREBRAL PALSY; CHOLINERGIC TRANSMISSION; CITRULLINEMIA; COGNITIVE DEFECT; DEMYELINATING DISEASE; DENDRITIC CELL; DISEASE MODEL; DISORDERS OF AMINO ACID AND PROTEIN METABOLISM; ENZYME DEFICIENCY; ENZYME SYNTHESIS; HUMAN; HYPERAMMONEMIA; LIVER TRANSPLANTATION; MITOCHONDRIAL PERMEABILITY; NERVE FIBER; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SEIZURE; SEROTONINERGIC SYSTEM; SIGNAL TRANSDUCTION; UREA CYCLE;

AMMONIA; ANIMALS; BRAIN; BRAIN DISEASES, METABOLIC, INBORN; CEREBRAL PALSY; CHILD; ENERGY METABOLISM; HUMANS; HYPERAMMONEMIA; MENTAL RETARDATION; NERVE DEGENERATION; RETT SYNDROME;

EID: 36048953322     PISSN: 01650173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresrev.2007.06.026     Document Type: Review

References (150)

1. Aguilar M.A., Minarro J., and Felipo V. Chronic moderate hyperammonemia impairs active and passive avoidance behavior and conditional discrimination learning in rats. Exp. Neurol. 161 (2000) 704-713
2. Aureli T., Miccheli A., Di Cocco M.E., Ghirardi O., Giuliani A., Ramacci M.T., and Conti F. Effect of acetyl-l-carnitine on recovery of brain phosphorus metabolites and lactic acid level during reperfusion after cerebral ischemia in the rat-study by 13P- and 1H-NMR spectroscopy. Brain Res. 643 (1994) 92-99
3. Azorin I., Minana M.D., Felipo V., and Grisolia S. A simple animal model of hyperammonemia. Hepatology 10 (1989) 311-314
4. Bachmann C. Ornithine carbamoyl transferase deficiency: findings, models and problems. J. Inherit. Metab. Dis. 15 (1992) 578-591
5. Bachmann C. Mechanisms of hyperammonemia. Clin. Chem. Lab. Med. 40 (2002) 653-662
6. Bachmann C. Outcome and survival of 88 patients with urea cycle disorders: a retrospective evaluation. Eur. J. Pediatr. 162 (2003) 410-416
7. Bachmann C., and Colombo J.P. Increase of tryptophan and 5-hydroxyindole acetic acid in the brain of ornithine carbamoyltransferase deficient sparse-fur mice. Pediatr. Res. 18 (1984) 372-375
8. Bachmann C., Braissant O., Villard A.M., Boulat O., and Henry H. Ammonia toxicity to the brain and creatine. Mol. Genet. Metab. 81 Suppl 1 (2004) S52-S57
9. Bai G., Rama Rao K.V., Murthy C.R., Panickar K.S., Jayakumar A.R., and Norenberg M.D. Ammonia induces the mitochondrial permeability transition in primary cultures of rat astrocytes. J. Neurosci. Res. 66 (2001) 981-991
10. Batshaw M.L., Robinson M.B., Hyland K., Djali S., and Heyes M.P. Quinolinic acid in children with congenital hyperammonemia. Ann. Neurol. 34 (1993) 676-681
11. Batshaw M.L., MacArthur R.B., and Tuchman M. Alternative pathway therapy for urea cycle disorders: twenty years later. J. Pediatr. 138 (2001) S46-S54
12. Berry G.T., and Steiner R.D. Long-term management of patients with urea cycle disorders. J. Pediatr. 138 (2001) S56-S60
13. Borsello T., Clarke P.G., Hirt L., Vercelli A., Repici M., Schorderet D.F., Bogousslavsky J., and Bonny C. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat. Med. 9 (2003) 1180-1186
14. Borsello T., Croquelois K., Hornung J.P., and Clarke P.G. N-methyl-d-aspartate-triggered neuronal death in organotypic hippocampal cultures is endocytic, autophagic and mediated by the c-Jun N-terminal kinase pathway. Eur. J. Neurosci. 18 (2003) 473-485
15. Braissant O. Neurofilament proteins in brain diseases. In: Arlen R.K. (Ed). New Research on Neurofilament Proteins (2006), Nova Science Publishers Inc., New York 25-51
16. Braissant O. Pathways depending on urea cycle intermediates. In: Bachmann C., Häberle J., Koch H.G., and Leonard J. (Eds). Pathophysiology and Management of Hyperammonemia (2007), SPS Publications, Heilbronn, Germany 25-41
17. Braissant O., Gotoh T., Loup M., Mori M., and Bachmann C. l-Arginine uptake, the citrulline-NO cycle and arginase II in the rat brain: an in situ hybridization study. Brain Res. Mol. Brain Res. 70 (1999) 231-241
18. Braissant O., Honegger P., Loup M., Iwase K., Takiguchi M., and Bachmann C. Hyperammonemia: regulation of argininosuccinate synthetase and argininosuccinate lyase genes in aggregating cell cultures of fetal rat brain. Neurosci. Lett. 266 (1999) 89-92
19. Braissant O., Gotoh T., Loup M., Mori M., and Bachmann C. Differential expression of the cationic amino acid transporter 2(B) in the adult rat brain. Brain Res. Mol. Brain Res. 91 (2001) 189-195
20. Braissant O., Henry H., Loup M., Eilers B., and Bachmann C. Endogenous synthesis and transport of creatine in the rat brain: an in situ hybridization study. Brain Res. Mol. Brain Res. 86 (2001) 193-201
21. Braissant O., Henry H., Villard A.M., Zurich M.G., Loup M., Eilers B., Parlascino G., Matter E., Boulat O., Honegger P., and Bachmann C. Ammonium-induced impairment of axonal growth is prevented through glial creatine. J. Neurosci. 22 (2002) 9810-9820
22. Braissant O., Henry H., Villard A.M., Speer O., Wallimann T., and Bachmann C. Creatine synthesis and transport during rat embryogenesis: spatiotemporal expression of AGAT, GAMT and CT1. BMC. Dev. Biol. 5 (2005) 9
23. Braissant O., Henry H., Cagnon L., Honegger P., and Bachmann C. Glial mechanisms of axonal growth protection from ammonia. In: Haussinger D. (Ed). Hepatic Encephalopathy and Nitrogen Metabolism (2006), Springer 124-133
24. Braissant O., Bachmann C., and Henry H. Expression and function of AGAT, GAMT and CT1 in the mammalian brain. Subcell. Biochem. 46 (2007) 67-81
25. Brewer G.J., and Wallimann T.W. Protective effect of the energy precursor creatine against toxicity of glutamate and beta-amyloid in rat hippocampal neurons. J. Neurochem. 74 (2000) 1968-1978
26. Brusilow S.W., and Maestri N.E. Urea cycle disorders: diagnosis, pathophysiology, and therapy. Adv. Pediatr. 43 (1996) 127-170
27. Brusilow S.W., and Horwich A.L. Urea Cycles Enzymes. The Metabolic and Molecular Bases of Inherited Disease. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds) (2001), McGraw-Hill, New York 1909-1963
28. Brusilow S.W., Valle D.L., and Batshaw M. New pathways of nitrogen excretion in inborn errors of urea synthesis. Lancet 2 (1979) 452-454
29. Butterworth R.F. Effects of hyperammonaemia on brain function. J. Inherit. Metab. Dis. 21 Suppl 1 (1998) 6-20
30. Butterworth R.F. Hepatic encephalopathy. Alcohol Res. Health 27 (2003) 240-246
31. Call G., Seay A.R., Sherry R., and Qureshi I.A. Clinical features of carbamyl phosphate synthetase-I deficiency in an adult. Ann. Neurol. 16 (1984) 90-93
32. Chan H., Hazell A.S., Desjardins P., and Butterworth R.F. Effects of ammonia on glutamate transporter (GLAST) protein and mRNA in cultured rat cortical astrocytes. Neurochem. Int. 37 (2000) 243-248
33. Chepkova A.N., Sergeeva O.A., and Haas H.L. Taurine rescues hippocampal long-term potentiation from ammonia-induced impairment. Neurobiol. Dis. 23 (2006) 512-521
34. Choi J.H., Kim H., and Yoo H.W. Two cases of citrullinaemia presenting with stroke. J. Inherit. Metab. Dis. 29 (2006) 182-183
35. Connelly A., Cross J.H., Gadian D.G., Hunter J.V., Kirkham F.J., and Leonard J.V. Magnetic resonance spectroscopy shows increased brain glutamine in ornithine carbamoyl transferase deficiency. Pediatr. Res. 33 (1993) 77-81
36. Cordoba J., and Blei A.T. Brain edema and hepatic encephalopathy. Semin. Liver Dis. 16 (1996) 271-280
37. Curis E., Nicolis I., Moinard C., Osowska S., Zerrouk N., Benazeth S., and Cynober L. Almost all about citrulline in mammals. Amino Acids 29 (2005) 177-205
38. D'Hooge R., Marescau B., Qureshi I.A., and De Deyn P.P. Impaired cognitive performance in ornithine transcarbamylase-deficient mice on arginine-free diet. Brain Res. 876 (2000) 1-9
39. de Grauw T.J., Smit L.M., Brockstedt M., Meijer Y., vd Klei-von M.J., and Jakobs C. Acute hemiparesis as the presenting sign in a heterozygote for ornithine transcarbamylase deficiency. Neuropediatrics 21 (1990) 133-135
40. de Knegt R.J., Schalm S.W., van der Rijt C.C., Fekkes D., Dalm E., and Hekking-Weyma I. Extracellular brain glutamate during acute liver failure and during acute hyperammonemia simulating acute liver failure: an experimental study based on in vivo brain dialysis. J. Hepatol. 20 (1994) 19-26
41. Deignan J.L., Livesay J.C., Yoo P.K., Goodman S.I., O'Brien W.E., Iyer R.K., Cederbaum S.D., and Grody W.W. Ornithine deficiency in the arginase double knockout mouse. Mol. Genet. Metab. 89 (2006) 87-96
42. DeMars R., LeVan S.L., Trend B.L., and Russell L.B. Abnormal ornithine carbamoyltransferase in mice having the sparse-fur mutation. Proc. Natl. Acad. Sci. U. S. A. 73 (1976) 1693-1697
43. Dolder M., Walzel B., Speer O., Schlattner U., and Wallimann T. Inhibition of the mitochondrial permeability transition by creatine kinase substrates. Requirement for microcompartmentation. J. Biol. Chem. 278 (2003) 17760-17766
44. Dolman C.L., Clasen R.A., and Dorovini-Zis K. Severe cerebral damage in ornithine transcarbamylase deficiency. Clin. Neuropathol. 7 (1988) 10-15
45. Donn S.M., and Banagale R.C. Neonatal hyperammonemia. Ped. Rev. 5 (1984) 203-208
46. Doolittle D.P., Hulbert L.L., and Cordy C. A new allele of the sparse fur gene in the mouse. J. Heredity 65 (1974) 194-195
47. Doyle A., Griffiths J.B., and Newel D.G. Cell and Tissue Culture: Laboratory Procedures (1994), Wiley, Chichester
48. Enns G.M., Berry S.A., Berry G.T., Rhead W.J., Brusilow S.W., and Hamosh A. Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. N. Engl. J. Med. 356 (2007) 2282-2292
49. Feillet F., and Leonard J.V. Alternative pathway therapy for urea cycle disorders. J. Inherit. Metab. Dis. 21 Suppl 1 (1998) 101-111
50. Felipo V., and Butterworth R.F. Neurobiology of ammonia. Prog. Neurobiol. 67 (2002) 259-279
51. Felipo V., Grau E., Minana M.D., and Grisolia S. Hyperammonemia decreases protein-kinase-C-dependent phosphorylation of microbule-associated protein 2 and increases its binding to tubulin. Eur. J. Biochem. 214 (1993) 243-249
52. Felipo V., Grau E., Minana M.D., and Grisolia S. Ammonium injection induces an N-methyl-D-aspartate receptor-mediated proteolysis of the microtubule-associated protein MAP-2. J. Neurochem. 60 (1993) 1626-1630
53. Filloux F., Townsend J.J., and Leonard C. Ornithine transcarbamylase deficiency: neuropathologic changes acquired in utero. J. Pediatr. 108 (1986) 942-945
54. Flint Beal M., and Martin J.B. Major complications of cirrhosis. In: Fauci A.S., Braunwald E., Isselbacher K.J., Wilson J.D., Martin J.B., Kasper D.L., Hauser S.L., and Longo D.L. (Eds). Harrison's Principles of Internal Medicine (1998), McGraw-Hill, New-York 2451-2457
55. Gropman A.L., and Batshaw M.L. Cognitive outcome in urea cycle disorders. Mol. Genet. Metab. 81 (2004) S58-S62
56. Gushiken T., Yoshimura N., and Saheki T. Transient hyperammonemia during aging in ornithine transcarbamylase-deficient, sparse-fur mice. Biochem. Int. 11 (1985) 637-643
57. Harada T., Morooka T., Ogawa S., and Nishida E. ERK induces p35, a neuron-specific activator of Cdk5, through induction of Egr1. Nat. Cell Biol. 3 (2001) 453-459
58. Harada E., Nishiyori A., Tokunaga Y., Watanabe Y., Kuriya N., Kumashiro R., Kuno T., Kuromaru R., Hirose S., Ichikawa K., and Yoshino M. Late-onset ornithine transcarbamylase deficiency in male patients: prognostic factors and characteristics of plasma amino acid profile. Pediatr. Int. 48 (2006) 105-111
59. Harding B.N., Leonard J.V., and Erdohazi M. Ornithine carbamoyl transferase deficiency: a neuropathological study. Eur. J. Pediatr. 141 (1984) 215-220
60. Harding B.N., Leonard J.V., and Erdohazi M. Propionic acidaemia: a neuropathological study of two patients presenting in infancy. Neuropathol. Appl. Neurobiol. 17 (1991) 133-138
61. Honegger P., and Monnet-Tschudi F. Aggregating neural cell culture. In: Fedoroff S., and Richardson E. (Eds). Protocols for Neural Cell Culture (2001), Humana Press, Inc., Totowa, NJ 199-218
62. Hopkins K.J., and Oster-Granite M.L. Characterization of N-methyl-d-aspartate receptors in the hyperammonemic sparse fur mouse. Brain Res. 797 (1998) 209-217
63. Hopkins K.J., McKean J., Mervis R.F., and Oster-Granite M.L. Dendritic alterations in cortical pyramidal cells in the sparse fur mouse. Brain Res. 797 (1998) 167-172
64. Husson A., Brasse-Lagnel C., Fairand A., Renouf S., and Lavoinne A. Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle. Eur. J. Biochem. 270 (2003) 1887-1899
65. Hyman S.L., Coyle J.T., Parke J.C., Porter C., Thomas G.H., Jankel W., and Batshaw M.L. Anorexia and altered serotonin metabolism in a patient with argininosuccinic aciduria. J. Pediatr. 108 (1986) 705-709
66. Hyman S.L., Porter C.A., Page T.J., Iwata B.A., Kissel R., and Batshaw M.L. Behavior management of feeding disturbances in urea cycle and organic acid disorders. J. Pediatr. 111 (1987) 558-562
67. Inoue I., Gushiken T., Kobayashi K., and Saheki T. Accumulation of large neutral amino acids in the brain of sparse-fur mice at hyperammonemic state. Biochem. Med. Metab. Biol. 38 (1987) 378-386
68. Iyer R.K., Yoo P.K., Kern R.M., Rozengurt N., Tsoa R., O'Brien W.E., Yu H., Grody W.W., and Cederbaum S.D. Mouse model for human arginase deficiency. Mol. Cell. Biol. 22 (2002) 4491-4498
69. Izumi Y., Izumi M., Matsukawa M., Funatsu M., and Zorumski C.F. Ammonia-mediated LTP inhibition: effects of NMDA receptor antagonists and l-carnitine. Neurobiol. Dis. 20 (2005) 615-624
70. Jayakumar A.R., Panickar K.S., Murthy C., and Norenberg M.D. Oxidative stress and mitogen-activated protein kinase phosphorylation mediate ammonia-induced cell swelling and glutamate uptake inhibition in cultured astrocytes. J. Neurosci. 26 (2006) 4774-4784
71. Kim I.S., Ki C.S., Kim J.W., Lee M., Jin D.K., and Lee S.Y. Characterization of late-onset citrullinemia 1 in a Korean patient: confirmation by argininosuccinate synthetase gene mutation analysis. J. Biochem. Mol. Biol. 39 (2006) 400-405
72. Klejman A., Wegrzynowicz M., Szatmari E.M., Mioduszewska B., Hetman M., and Albrecht J. Mechanisms of ammonia-induced cell death in rat cortical neurons: roles of NMDA receptors and glutathione. Neurochem. Int. 47 (2005) 51-57
73. Kosenko E., Kaminsky Y., Kaminsky A., Valencia M., Lee L., Hermenegildo C., and Felipo V. Superoxide production and antioxidant enzymes in ammonia intoxication in rats. Free Radic. Res. 27 (1997) 637-644
74. Kosenko E., Kaminsky Y., Lopata O., Muravyov N., Kaminsky A., Hermenegildo C., and Felipo V. Nitroarginine, an inhibitor of nitric oxide synthase, prevents changes in superoxide radical and antioxidant enzymes induced by ammonia intoxication. Metab. Brain Dis. 13 (1998) 29-41
75. Kosenko E., Kaminski Y., Lopata O., Muravyov N., and Felipo V. Blocking NMDA receptors prevents the oxidative stress induced by acute ammonia intoxication. Free Radic. Biol. Med. 26 (1999) 1369-1374
76. Kroemer G., Galluzzi L., and Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 87 (2007) 99-163
77. Kurihara A., Takanashi J., Tomita M., Kobayashi K., Ogawa A., Kanazawa M., Yamamoto S., and Kohno Y. Magnetic resonance imaging in late-onset ornithine transcarbamylase deficiency. Brain Develop. 25 (2003) 40-44
78. Lai J.C., and Cooper A.J. Brain alpha-ketoglutarate dehydrogenase complex: kinetic properties, regional distribution, and effects of inhibitors. J. Neurochem. 47 (1986) 1376-1386
79. Lee B., and Goss J. Long-term correction of urea cycle disorders. J. Pediatr. 138 (2001) S62-S71
80. Leonard J.V., and Morris A.A.M. Urea cycle disorders. Semin. Neonatol. 7 (2002) 27-35
81. Leonard, J.V., Ward Platt, M.P., Morris, A.A., in press. Hypothesis: proposals for the management of a neonate at risk of hyperammonaemia due to a urea cycle disorder. Eur. J. Pediatr. (Electronic publication ahead of print). doi:10.1007/s00431-007-0486-z.
82. Majoie C.B., Mourmans J.M., Akkerman E.M., and Duran M. Poll-The BT, 2004. Neonatal citrullinemia: comparison of conventional MR, diffusion-weighted, and diffusion tensor findings. Am. J. Neuroradiol. 25 (2004) 32-35
83. Marcaida G., Minana M.D., Grisolia S., and Felipo V. Lack of correlation between glutamate-induced depletion of ATP and neuronal death in primary cultures of cerebellum. Brain Res. 695 (1995) 146-150
84. Marini J.C., Lee B., and Garlick P.J. Ornithine restores ureagenesis capacity and mitigates hyperammonemia in Otc(spf-ash) mice. J. Nutr. 136 (2006) 1834-1838
85. Marini J.C., Lee B., and Garlick P.J. Reduced ornithine transcarbamylase activity does not impair ureagenesis in Otc(spf-ash) mice. J. Nutr. 136 (2006) 1017-1020
86. Mehta S.L., Manhas N., and Raghubir R. Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res. Rev. 54 (2007) 34-66
87. Michalak A., and Butterworth R.F. Ornithine transcarbamylase deficiency: pathogenesis of the cerebral disorder and new prospects for therapy. Metab. Brain Dis. 12 (1997) 171-182
88. Mielke K., and Herdegen T. JNK and p38 stress kinases-degenerative effectors of signal-transduction-cascades in the nervous system. Prog. Neurobiol. 61 (2000) 45-60
89. Moncada S., and Bolanos J.P. Nitric oxide, cell bioenergetics and neurodegeneration. J. Neurochem. 97 (2006) 1676-1689
90. Morris S.M. Regulation of enzymes of the urea cycle and arginine metabolism. Annu. Rev. Nutr. 22 (2002) 87-105
91. Morris S.M. Recent advances in arginine metabolism. Curr. Opin. Clin. Nutr. Metab. Care 7 (2004) 45-51
92. Msall M., Batshaw M.L., Suss R., Brusilow S.W., and Mellits E.D. Neurologic outcome in children with inborn errors of urea synthesis. Outcome of urea-cycle enzymopathies. N. Engl. J. Med. 310 (1984) 1500-1505
93. Msall M., Monahan P.S., Chapanis N., and Batshaw M.L. Cognitive development in children with inborn errors of urea synthesis. Acta Paediatr. Jpn. 30 (1988) 435-441
94. Munoz M.D., Monfort P., Gaztelu J.M., and Felipo V. Hyperammonemia impairs NMDA receptor-dependent long-term potentiation in the CA1 of rat hippocampus in vitro. Neurochem. Res. 25 (2000) 437-441
95. Murthy C.R., Rama Rao K.V., Bai G., and Norenberg M.D. Ammonia-induced production of free radicals in primary cultures of rat astrocytes. J. Neurosci. Res. 66 (2001) 282-288
96. Nagasaka H., Komatsu H., Ohura T., Sogo T., Inui A., Yorifuji T., Murayama K., Takayanagi M., Kikuta H., and Kobayashi K. Nitric oxide synthesis in ornithine transcarbamylase deficiency: possible involvement of low no synthesis in clinical manifestations of urea cycle defect. J. Pediatr. 145 (2004) 259-262
97. Nagata N., Matsuda I., Matsuura T., Oyanagi K., Tada K., Narisawa K., Kitagawa T., Sakiyama T., Yamashita F., and Yoshino M. Retrospective survey of urea cycle disorders: Part 2. Neurological outcome in forty-nine Japanese patients with urea cycle enzymopathies. Am. J. Med. Genet. 40 (1991) 477-481
98. Nishie M., Mori F., Houzen H., Yamaguchi J., Jensen P.H., and Wakabayashi K. Oligodendrocytes within astrocytes ("emperipolesis") in the cerebral white matter in hepatic and hypoglycemic encephalopathy. Neuropathology 26 (2006) 62-65
99. Norenberg M.D., Rao K.V., and Jayakumar A.R. Mechanisms of ammonia-induced astrocyte swelling. Metab. Brain Dis. 20 (2005) 303-318
100. O'Gorman E., Beutner G., Dolder M., Koretsky A.P., Brdiczka D., and Wallimann T. The role of creatine kinase in inhibition of mitochondrial permeability transition. FEBS Lett. 414 (1997) 253-257
101. Qureshi I.A., and Rao K.V. Sparse-fur (spf) mouse as a model of hyperammonemia: alterations in the neurotransmitter systems. Adv. Exp. Med. Biol. 420 (1997) 143-158
102. Qureshi I.A., Letarte J., and Ouellet R. Ornithine transcarbamylase deficiency in mutant mice I. Studies on the characterization of enzyme defect and suitability as animal model of human disease. Pediatr. Res. 13 (1979) 807-811
103. Rao V.L. Nitric oxide in hepatic encephalopathy and hyperammonemia. Neurochem. Int. 41 (2002) 161-170
104. Rao K.V., and Qureshi I.A. Reduction in the MK-801 binding sites of the NMDA sub-type of glutamate receptor in a mouse model of congenital hyperammonemia: prevention by acetyl-l-carnitine. Neuropharmacology 38 (1999) 383-394
105. Rao K.V., Mawal Y.R., and Qureshi I.A. Progressive decrease of cerebral cytochrome C oxidase activity in sparse-fur mice: role of acetyl-l-carnitine in restoring the ammonia-induced cerebral energy depletion. Neurosci. Lett. 224 (1997) 83-86
106. Ratnakumari L., Qureshi I.A., and Butterworth R.F. Effects of congenital hyperammonemia on the cerebral and hepatic levels of the intermediates of energy metabolism in spf mice. Biochem. Biophys. Res. Commun. 184 (1992) 746-751
107. Ratnakumari L., Qureshi I.A., and Butterworth R.F. Regional amino acid neurotransmitter changes in brains of spf/Y mice with congenital ornithine transcarbamylase deficiency. Metab. Brain Dis. 9 (1994) 43-51
108. Ratnakumari L., Qureshi I.A., and Butterworth R.F. Evidence for cholinergic neuronal loss in brain in congenital ornithine transcarbamylase deficiency. Neurosci. Lett. 178 (1994) 63-65
109. Ratnakumari L., Qureshi I.A., and Butterworth R.F. Loss of [3H]MK801 binding sites in brain in congenital ornithine transcarbamylase deficiency. Metab. Brain Dis. 10 (1995) 249-255
110. Ratnakumari L., Qureshi I.A., Maysinger D., and Butterworth R.F. Developmental deficiency of the cholinergic system in congenitally hyperammonemic spf mice: effect of acetyl-l-carnitine. J. Pharmacol. Exp. Ther. 274 (1995) 437-443
111. Ratnakumari L., Qureshi I.A., and Butterworth R.F. Central muscarinic cholinergic M1 and M2 receptor changes in congenital ornithine transcarbamylase deficiency. Pediatr. Res. 40 (1996) 25-28
112. Ratnakumari L., Qureshi I.A., Butterworth R.F., Marescau B., and De Deyn P.P. Arginine-related guanidino compounds and nitric oxide synthase in the brain of ornithine transcarbamylase deficient spf mutant mouse: effect of metabolic arginine deficiency. Neurosci. Lett. 215 (1996) 153-156
113. Reid Sutton V., Pan Y., Davis E.C., and Craigen W.J. A mouse model of argininosuccinic aciduria: biochemical characterization. Mol. Genet. Metab. 78 (2003) 11-16
114. Reinehr R., Gorg B., Becker S., Qvartskhava N., Bidmon H.J., Selbach O., Haas H.L., Schliess F., and Haussinger D. Hypoosmotic swelling and ammonia increase oxidative stress by NADPH oxidase in cultured astrocytes and vital brain slices. Glia 55 (2007) 758-771
115. Robinson M.B., Anegawa N.J., Gorry E., Qureshi I.A., Coyle J.T., Lucki I., and Batshaw M.L. Brain serotonin2 and serotonin1A receptors are altered in the congenitally hyperammonemic sparse fur mouse. J. Neurochem. 58 (1992) 1016-1022
116. Robinson M.B., Heyes M.P., Anegawa N.J., Gorry E., Djali S., Mellits E.D., and Batshaw M.L. Quinolinate in brain and cerebrospinal fluid in rat models of congenital hyperammonemia. Pediatr. Res. 32 (1992) 483-488
117. Robinson M.B., Hopkins K., Batshaw M.L., McLaughlin B.A., Heyes M.P., and Oster-Granite M.L. Evidence of excitotoxicity in the brain of the ornithine carbamoyltransferase deficient sparse fur mouse. Brain Res. Dev. Brain Res. 90 (1995) 35-44
118. Rodrigo R., and Felipo V. Brain regional alterations in the modulation of the glutamate-nitric oxide-cGMP pathway in liver cirrhosis. Role of hyperammonemia and cell types involved. Neurochem. Int. 48 (2006) 472-477
119. Rodrigo R., Erceg S., and Felipo V. Neurons exposed to ammonia reproduce the differential alteration in nitric oxide modulation of guanylate cyclase in the cerebellum and cortex of patients with liver cirrhosis. Neurobiol. Dis. 19 (2005) 150-161
120. Rose C., and Felipo V. Limited capacity for ammonia removal by brain in chronic liver failure: potential role of nitric oxide. Metab. Brain Dis. 20 (2005) 275-283
121. Rose C., Kresse W., and Kettenmann H. Acute insult of ammonia leads to calcium-dependent glutamate release from cultured astrocytes, an effect of pH. J. Biol. Chem. 280 (2005) 20937-20944
122. Russell R.W. Continuing the search for cholinergic factors in cognitive dysfunction. Life Sci. 58 (1996) 1965-1970
123. Salvi S., Santorelli F.M., Bertini E., Boldrini R., Meli C., Donati A., Burlina A.B., Rizzo C., Di Capua M., Fariello G., and onisi-Vici C. Clinical and molecular findings in hyperornithinemia-hyperammonemia-homocitrullinuria syndrome. Neurology 57 (2001) 911-914
124. Scaglia F., and Lee B. Clinical, biochemical, and molecular spectrum of hyperargininemia due to arginase I deficiency. Am. J. Med. Genet. C. Semin. Med. Genet. 142 (2006) 113-120
125. Scaglia F., Zheng Q., O'Brien W.E., Henry J., Rosenberger J., Reeds P., and Lee B. An integrated approach to the diagnosis and prospective management of partial ornithine transcarbamylase deficiency. Pediatrics 109 (2002) 150-152
126. Scaglia F., Brunetti-Pierri N., Kleppe S., Marini J., Carter S., Garlick P., Jahoor F., O'Brien W., and Lee B. Clinical consequences of urea cycle enzyme deficiencies and potential links to arginine and nitric oxide metabolism. J. Nutr. 134 (2004) 2775S-2782S
127. Schliess F., Gorg B., Fischer R., Desjardins P., Bidmon H.J., Herrmann A., Butterworth R.F., Zilles K., and Haussinger D. Ammonia induces MK-801-sensitive nitration and phosphorylation of protein tyrosine residues in rat astrocytes. FASEB J. 16 (2002) 739-741
128. Schwarcz R., and Kohler C. Differential vulnerability of central neurons of the rat to quinolinic acid. Neurosci. Lett. 38 (1983) 85-90
129. Shih V.E. Alternative-pathway therapy for hyperammonemia. N. Engl. J. Med. 356 (2007) 2321-2322
130. Smith W., Kishnani P.S., Lee B., Singh R.H., Rhead W.J., Sniderman K.L., Smith M., and Summar M. Urea cycle disorders: clinical presentation outside the newborn period. Crit. Care Clin. 21 (2005) S9-S17
131. Song G., Dhodda V.K., Blei A.T., Dempsey R.J., and Rao V.L. GeneChip analysis shows altered mRNA expression of transcripts of neurotransmitter and signal transduction pathways in the cerebral cortex of portacaval shunted rats. J. Neurosci. Res. 68 (2002) 730-737
132. Stanciu M., Wang Y., Kentor R., Burke N., Watkins S., Kress G., Reynolds I., Klann E., Angiolieri M.R., Johnson J.W., and DeFranco D.B. Persistent activation of ERK contributes to glutamate-induced oxidative toxicity in a neuronal cell line and primary cortical neuron cultures. J. Biol. Chem. 275 (2000) 12200-12206
133. Summar M. Current strategies for the management of neonatal urea cycle disorders. J. Pediatr. 138 (2001) S30-S39
134. Takanashi J., Kurihara A., Tomita M., Kanazawa M., Yamamoto S., Morita F., Ikehira H., Tanada S., and Kohno Y. Distinctly abnormal brain metabolism in late-onset ornithine transcarbamylase deficiency. Neurology 59 (2002) 210-214
135. Takanashi J., Barkovich A.J., Cheng S.F., Kostiner D., Baker J.C., and Packman S. Brain MR imaging in acute hyperammonemic encephalopathy arising from late-onset ornithine transcarbamylase deficiency. Am. J. Neuroradiol. 24 (2003) 390-393
136. Takanashi J., Barkovich A.J., Cheng S.F., Weisiger K., Zlatunich C.O., Mudge C., Rosenthal P., Tuchman M., and Packman S. Brain MR imaging in neonatal hyperammonemic encephalopathy resulting from proximal urea cycle disorders. Am. J. Neuroradiol. 24 (2003) 1184-1187
137. Takeoka M., Soman T.B., Shih V.E., Caviness V.S., and Krishnamoorthy K.S. Carbamyl phosphate synthetase 1 deficiency: a destructive encephalopathy. Pediatr. Neurol. 24 (2001) 193-199
138. Uchino T., Endo F., and Matsuda I. Neurodevelopmental outcome of long-term therapy of urea cycle disorders in Japan. J. Inherit. Metab. Dis. 21 Suppl 1 (1998) 151-159
139. Veeranna, Amin N.D., Ahn N.G., Jaffe H., Winters C.A., Grant P., and Pant H.C. Mitogen-activated protein kinases (Erk1,2) phosphorylate Lys-Ser-Pro (KSP) repeats in neurofilament proteins NF-H and NF-M. J. Neurosci. 18 (1998) 4008-4021
140. Veres G., Gibbs R.A., Sherer S.E., and Caskey C.T. The molecular basis of the sparse fur mouse mutation. Science 237 (1987) 415-417
141. Wakabayashi Y. Tissue-selective expression of enzymes of arginine synthesis. Curr. Opin. Clin. Nutr. Metab. Care 1 (1998) 335-339
142. Wakamoto H., Manabe K., Kobayashi H., and Hayashi M. Subclinical portal-systemic encephalopathy in a child with congenital absence of the portal vein. Brain Develop. 21 (1999) 425-428
143. Wiesinger H. Arginine metabolism and the synthesis of nitric oxide in the nervous system. Prog. Neurobiol. 64 (2001) 365-391
144. Wilken B., Ramirez J.M., Probst I., Richter D.W., and Hanefeld F. Anoxic ATP depletion in neonatal mice brainstem is prevented by creatine supplementation. Arch. Dis. Child., Fetal Neonatal Ed. 82 (2000) F224-F227
145. Wu G., and Morris S.M. Arginine metabolism: nitric oxide and beyond. Biochem. J. 336 (1998) 1-17
146. Wyss M., and Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol. Rev. 80 (2000) 1107-1213
147. Xia Z., Dickens M., Raingeaud J., Davis R.J., and Greenberg M.E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270 (1995) 1326-1331
148. Yamanouchi H., Yokoo H., Yuhara Y., Maruyama K., Sasaki A., Hirato J., and Nakazato Y. An autopsy case of ornithine transcarbamylase deficiency. Brain Develop. 24 (2002) 91-94
149. Yu H., Iyer R.K., Kern R.M., Rodriguez W.I., Grody W.W., and Cederbaum S.D. Expression of arginase isozymes in mouse brain. J. Neurosci. Res. 66 (2001) 406-422
150. Zanelli S.A., Solenski N.J., Rosenthal R.E., and Fiskum G. Mechanisms of ischemic neuroprotection by acetyl-l-carnitine. Ann. N.Y. Acad. Sci. 1053 (2005) 153-161